The DAPA-HF trial, the first to investigate the impact of SGLT-2 inhibitors on HF outcomes in patients with or without type 2 diabetes (HFrEF), demonstrated that DAPA significantly reduced the risk of worsening HF (hospitalization or an urgent visit resulting in intravenous therapy for HF) or cardiovascular death in HFrEF patients when added to standard HF treatment [8]. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.